Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease

During the 24-week dapagliflozin treatment, there was a decrease in skeletal muscle index and extracellular water-to-total body water ratio with unchanged handgrip strength in patients with chronic kidney disease. Sarcopenia prevalence remained constant. Therefore, regarding sarcopenia, short-term dapagliflozin administration might be safe. However, further long-term studies are required to determine the safety of dapagliflozin in these patients.